What we're reading, June 29, 2016: CMS is considering changes to the proposed Medicare Part B demonstration; Senate Democrats block the GOP's Zika funding bill; and a Bloomberg analysis shines light on the pricing practices of the pharmaceutical industry.
A proposed change to Medicare Part B payment that has been met with some dissatisfaction from providers and patient groups could change in response to comments CMS received. According to The Wall Street Journal, Patrick Conway, MD, acting deputy administrator at CMS, said the agency is reviewing the more than 1300 public comments about the proposal and could alter the plan. Opponents to the proposal are concerned that it will limit seniors’ access to drugs. The proposed program would test changes to how providers are reimbursed for administering drugs in offices or outpatient settings.
Senate Democrats have blocked the GOP bill to fund the fight against the Zika virus. Democrats refused to pass the bill because Republicans had included in it provisions to deny new funding for Planned Parenthood clinics in Puerto Rico, reported AP. The legislation proposed funding of $1.1 billion, short of President Obama’s request of $1.9 billion. With the bill being blocked and Congress preparing for a 7-week vacation, it is unclear if a bill with funding to fight the virus will be passed.
In a special report, Bloomberg highlighted the secret drug pricing practices of the pharmaceutical industry. The analysis found even after estimated discounts are factored in, 30 of 39 medicines with global sales topping $1 billion a year had price increases that were more than double the rate of inflation from 2009 to 2015. Discounted prices for 27 drugs rose at rates of 25% or more compared with an increase of 9.5% for the consumer price index.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More